Less Ads, More Data, More Tools Register for FREE

Pin to quick picksThruvision Grp Regulatory News (THRU)

Share Price Information for Thruvision Grp (THRU)

Share Price is delayed by 15 minutes
Get Live Data
0.725    0.00 (0.00%)
Bid:
0.70
Ask:
0.75
Spread: 0.05 (7.143%)
Market Cap: £3.24m
THRU Live PriceLast checked at - London Stock Exchange

Intraday Thruvision Grp Share Chart

Pre-close Trading Update

2 Apr 2019 07:00

RNS Number : 7584U
Thruvision Group PLC
02 April 2019
 

2 April 2019

 

Thruvision Group plc

 

("Thruvision" or the "Group")

 

Pre-close Trading Update

 

 

Thruvision (AIM: THRU) the specialist provider of people-screening technology to the international security market, is pleased to provide an update on trading for the year to 31 March 2019.

 

Good momentum was maintained across all four of the Group's key markets, with a further 50 units delivered to customers in H2. This brought the full year total to 109 units (FY18: 57 units) with revenues expected to be in the order of £6.0 million (FY18: £3.1 million). Cash at 31 March 2019, following the return of cash to shareholders in August 2018, was £9.4 million (31 March 2018: £17.4 million).

 

Second half sales included a third order from an existing Asian government customer for transportation security, repeat orders from four existing Loss Prevention customers (Next, Sony, Boots and Hermes), and Matalan becoming a new customer. Good progress was made in our Customs market with UK Border Force, US State Department's Bureau of International Narcotics and Law Enforcement Affairs and a national European Customs agency all purchasing units for the first time.

 

Our sales pipeline continues to build, especially in the US. Although activity here was affected by the government shutdown early in 2019, several initiatives in the Customs and Aviation Security markets are now gathering momentum and our broader strategic sales pipeline in these areas continues to strengthen. Manufacturing ramp up by our US partner company has been successful.

 

The combination of new customer wins, strong progress in the US and repeat customer purchases in both our Asia and Loss Prevention markets, supports the Board's confidence in the strategic prospects for the Group.

 

 

 

For further information please contact:

 

Thruvision Group plc +44 (0)20 3553 5888

Tom Black, Executive Chairman

Colin Evans, Managing Director

 

Investec Investment Banking (NOMAD & Broker) +44 (0)20 7597 5970

Andrew Pinder / Sebastian Lawrence / Patrick Robb

 

FTI Consulting LLP +44 (0)20 3727 1000

Matt Dixon / Harry Staight

 

 

 

About Thruvision

Thruvision Group plc is a specialist provider of people-screening technology that can safely see weapons, explosives and contraband hidden in peoples' clothing. Developed with extensive support from the British and US Governments, Thruvision technology is operationally proven and is being used to enhance the security of transport hubs, borders, high profile buildings and public areas.

 

 

www.thruvision.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLLFSASSILIIA
Date   Source Headline
2nd Apr 20207:40 amRNSTrading Statement
25th Nov 20197:00 amRNSInterim Results
19th Nov 20197:00 amRNSNotice of Interim Results
13th Nov 20193:28 pmRNSHolding(s) in Company
24th Oct 20197:00 amRNSSharesave option grant to Executive Director
8th Oct 20192:00 pmRNSAward of Share Options to Executive Directors
3rd Oct 20197:00 amRNSTrading Update
23rd Sep 20191:29 pmRNSResult of Annual General Meeting
23rd Sep 20197:00 amRNSContract award announcement
16th Sep 20193:36 pmRNSThruvision trialed in London Underground station
8th Jul 20192:14 pmRNSNotice of Audited Results
24th Jun 20197:00 amRNSResults for the Year ended 31 March 2019
20th Jun 20197:00 amRNSNotice of Results
22nd May 20197:00 amRNSContract award announcement
1st May 20197:00 amRNSAppointment of Finance Director
2nd Apr 20197:00 amRNSPre-close Trading Update
7th Feb 20197:00 amRNSCapital Markets Day
18th Jan 20194:02 pmRNSAward of Share Options to Executive Directors
10th Dec 20187:00 amRNSInterim Results
3rd Dec 201812:52 pmRNSNotice of Results
2nd Nov 20181:24 pmRNSTSA Concept of Operations Development Contract
3rd Oct 20187:00 amRNSTrading Update
21st Sep 20183:57 pmRNSSharesave option grant to Executive Directors
21st Sep 201810:21 amRNSAGM Statement
7th Sep 20185:10 pmRNSHolding(s) in Company
7th Sep 20185:07 pmRNSHolding(s) in Company
24th Aug 20189:19 amRNSAmendment - Holding(s) in Company
22nd Aug 201811:30 amRNSHolding(s) in Company
21st Aug 201810:52 amRNSHolding(s) in Company
20th Aug 20183:04 pmRNSHolding(s) in Company
20th Aug 20182:53 pmRNSHolding(s) in Company
9th Aug 201812:30 pmRNSAnnouncement of Results of Tender Offer
31st Jul 20189:00 amRNSHolding(s) in Company
24th Jul 201810:21 amRNSResults of General Meeting/Tender Offer
4th Jul 20187:00 amRNSProposed Tender Offer & Notice of General Meeting
26th Jun 20187:00 amRNSAudited results for the full year 31 March 2018
21st Jun 201811:26 amRNSNotice of Audited Results
1st May 20183:53 pmRNSCapital Reduction Effective
28th Mar 20183:25 pmRNSResult of General Meeting
15th Mar 20185:13 pmRNSHolding(s) in Company
15th Mar 20182:00 pmRNSHolding(s) in Company
15th Mar 20187:00 amRNSDirector/PDMR Shareholding
15th Mar 20187:00 amRNSAward of Share Options to Executive Director
13th Mar 20185:29 pmRNSHolding(s) in Company
13th Mar 20183:40 pmRNSHolding(s) in Company
13th Mar 20183:17 pmRNSHolding(s) in Company
12th Mar 20182:05 pmRNSSecond Price Monitoring Extn
12th Mar 20182:02 pmRNSPrice Monitoring Extension
12th Mar 20187:01 amRNSShare Premium Account & Capital Redemption Reserve
12th Mar 20187:00 amRNSTrading Update & Return of Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.